Clinical trials for Lung cancer
300 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Lung cancer
#NCT04614103
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
Excluded genetic anomalies
ALK
EGFR
ROS-1
6 recruiting sites
Iovance Biotherapeutics
Phase 2
Lung cancer
#NCT06465329
#2023-509806-31-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
Excluded previous treatments at localized stage
Radiotherapy
7 recruiting sites
Regeneron Pharmaceuticals
Phase 2
Lung cancer
#NCT07016230
#2024-515847-47-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2
Lung cancer
#NCT05498428
#2023-505065-91-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None
1
2
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Targeted therapy
5 recruiting sites
Janssen
Phase 2
Lung cancer
#NCT05498428
#2023-505065-91-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Bispecific T-cell engager antibodies
5 recruiting sites
Janssen
Phase 2
Lung cancer
#NCT04400539
#2024-514103-33-00
Required histologic types
Mesothelium
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
1 recruiting site
Phase 2
Lung cancer
#NCT06868485
#2024-519713-65-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Wayshine Biopharm, Inc.
Phase 2
Lung cancer
#NCT05498428
#2023-505065-91-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Bispecific T-cell engager antibodies
5 recruiting sites
Janssen
Phase 2
Lung cancer
#NCT05865730
#2024-516711-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
2 recruiting sites
EverImmune
Phase 2
Lung cancer
#NCT05498428
#2023-505065-91-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Janssen